These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36777344)

  • 1. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.
    Cai H; Chen Q; Duan Y; Zhao Y; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1106868. PubMed ID: 36777344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial.
    Zhang S; Zhang C; Chen J; Deng F; Wu Z; Zhu D; Chen F; Duan Y; Zhao Y; Hou K
    Front Pharmacol; 2023; 14():1171399. PubMed ID: 37214446
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial.
    Cao Y; Cao S; Zhao J; Zhao J; Zhao Y; Liu Y
    Front Endocrinol (Lausanne); 2024; 15():1387993. PubMed ID: 39099671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: a systematic review and meta-analysis.
    Liu Y; Ma W; Fu H; Zhang Z; Yin Y; Wang Y; Liu W; Yu S; Zhang Z
    Front Pharmacol; 2024; 15():1235639. PubMed ID: 38469407
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3).
    Xie Y; Kuang J; Li Q; Hong T; Ji L; Kong Y; Duan Y; Chen L
    BMJ Open; 2023 May; 13(5):e069080. PubMed ID: 37192802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy of Polyethylene Glycol Loxenatide in the Treatment of Obese or Overweight Patients with Type 2 Diabetes Mellitus.
    Song X; Yao M; Li Z; Guo S; Yin F; Li R
    J Coll Physicians Surg Pak; 2023 Dec; 33(12):1390-1394. PubMed ID: 38062594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
    Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
    Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in
    Zhang Y; Li Y; Zhao J; Wang C; Deng B; Zhang Q; Shi C
    Front Pharmacol; 2021; 12():781856. PubMed ID: 34938192
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
    Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
    JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
    Tanaka K; Saisho Y; Kawai T; Tanaka M; Meguro S; Irie J; Imai T; Shigihara T; Morimoto J; Yajima K; Atsumi Y; Takei I; Itoh H
    Endocr J; 2015; 62(5):399-409. PubMed ID: 25739726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
    Elkind-Hirsch KE; Seidemann E; Harris R
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100139. PubMed ID: 33345876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
    Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
    JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients.
    Chen X; Lv X; Yang G; Lu D; Piao C; Zhang X; Jiang H; Xie Y; Yang J; Li X; Li Y; Xiao X; Li Y; Sun L; Zheng S; Cheng Q; Peng Y; Yang W
    J Diabetes; 2017 Feb; 9(2):158-167. PubMed ID: 26989888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
    Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
    Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial.
    Gao F; Lv X; Mo Z; Ma J; Zhang Q; Yang G; Liu W; Li Q; Zhou J; Bao Y; Jia W
    Diabetes Obes Metab; 2020 Dec; 22(12):2375-2383. PubMed ID: 32744358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.
    Liu L; Ruan Z; Ung COL; Zhang Y; Shen Y; Han S; Jia R; Qiao J; Hu H; Guo L
    Diabetes Ther; 2023 Jan; 14(1):93-107. PubMed ID: 36414806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.
    Ji L; Li H; Guo X; Li Y; Hu R; Zhu Z
    PLoS One; 2013; 8(2):e57222. PubMed ID: 23468941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.